Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Rezolute , Inc. (NASDAQ:RZLT) Chief Financial Officer Daron Evans has recently purchased 5,000 shares of the company’s common stock at $4.05 per share, according to a Form 4 filing with the Securities and Exchange Commission. The total value of the purchase was $20,250. The purchase comes as InvestingPro data shows the stock trading at $4.20, with analyst targets ranging from $9 to $15, suggesting significant upside potential. The company maintains a strong financial position with a healthy current ratio of 8.43, indicating robust liquidity.
Following the transaction on June 24, 2025, Evans directly owns 268,900 shares of Rezolute, Inc. In addition, he indirectly owns 23,000 shares held by minor child #1, 4,500 shares held by minor child #2, 4,500 shares held by minor child #3, 20,000 shares held by spouse and 40,000 shares held by PoC Capital LLC, a California limited liability company managed by Evans. Get deeper insights into insider trading patterns and comprehensive financial analysis with InvestingPro, which offers exclusive access to detailed research reports covering 1,400+ US stocks.
In other recent news, Rezolute, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its drug candidate ersodetug for treating hypoglycemia caused by tumor hyperinsulinism. This designation is based on clinical data suggesting significant improvements over existing treatments. Additionally, Rezolute has completed enrollment for its Phase 3 sunRIZE clinical trial, which is evaluating ersodetug for congenital hyperinsulinism, with top-line results expected in December 2025. The Independent (LON:IOG) Data Monitoring Committee has recommended continuing the trial without changes, affirming the study’s initial design.
In financial developments, Rezolute plans a public offering aiming to raise approximately $90 million, with proceeds directed toward research and development and general corporate expenses. This offering includes common stock and pre-funded warrants, with Guggenheim Securities as the sole book-running manager. Analyst Julian Harrison from BTIG has maintained a Buy rating on Rezolute with a $15 price target, citing confidence in the sunRIZE trial’s potential success. Furthermore, Rezolute has expanded its Board of Directors by appointing Erik Harris, a biopharma veteran, to support its strategic growth and commercialization efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.